[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498421":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":402,"collaborators":404,"id":414,"slug":32,"hasResults":415,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":415,"sex":421,"minAge":32,"maxAge":32,"enrollmentInfo":422,"targetDuration":32,"studyType":425,"phases":426,"briefSummary":429,"conditions":430,"keywords":442,"overallStatus":37,"whyStopped":32,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":467},{"fullName":5,"class":6},"Cancer Research UK","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm 01: Alectinib","EXPERIMENTAL","This alectinib treatment arm is for adult, paediatric and teenage\u002Fyoung adult (TYA) patients with ALK-positive cancers.",[13],"Drug: Alectinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Alectinib","Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.\n\nPaediatric patients with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.\n\nEach cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[9],[21],"Alecensa",[23],{"name":24,"affiliation":25,"role":26},"Matthew Krebs, Dr","The Christie Hospital","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Aida Sarmiento Castro","CONTACT","+44 207 242 0200",null,"determine@cancer.org.uk",[35,53,68,80,95,104,119,135,147,160,175,187,202,217,232,244,256,271,281,296,311,321,336,345,360,372,387],{"facility":36,"status":37,"city":38,"state":32,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Belfast City Hospital","RECRUITING","Belfast","BT9 7AB","United Kingdom","UK",{"type":43,"coordinates":44},"Point",[45,46],-5.92541,54.59682,{"lat":46,"lon":45},[49,52],{"name":50,"role":30,"phone":32,"phoneExt":32,"email":51},"Vicky Coyle, Prof","V.Coyle@qub.ac.uk",{"name":50,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":54,"status":37,"city":55,"state":32,"zip":56,"country":40,"countryCode":41,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"University Hospital Birmingham","Birmingham","B15 2TT",{"type":43,"coordinates":58},[59,60],-1.89983,52.48142,{"lat":60,"lon":59},[63,67],{"name":64,"role":30,"phone":65,"phoneExt":32,"email":66},"Gary Middleton, Prof","0121 371 3573","G.Middleton@bham.ac.uk",{"name":64,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":69,"status":70,"city":55,"state":32,"zip":32,"country":40,"countryCode":41,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Birmingham Children's Hospital","NOT_YET_RECRUITING",{"type":43,"coordinates":72},[59,60],{"lat":60,"lon":59},[75,79],{"name":76,"role":30,"phone":77,"phoneExt":32,"email":78},"Gerard Millen, Dr","07921843607","g.millen@nhs.net",{"name":76,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":81,"status":37,"city":82,"state":32,"zip":83,"country":40,"countryCode":41,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Bristol Royal Hospital for Children","Bristol","BS2 8BJ",{"type":43,"coordinates":85},[86,87],-2.59665,51.45523,{"lat":87,"lon":86},[90,94],{"name":91,"role":30,"phone":92,"phoneExt":32,"email":93},"Antony Ng, Dr","0117 342 8044","Antony.Ng@uhbw.nhs.uk",{"name":91,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":96,"status":37,"city":82,"state":32,"zip":97,"country":40,"countryCode":41,"cosmosGeoPoint":98,"geoPoint":100,"contacts":101},"Bristol Haematology and Oncology Centre","BS2 8ED",{"type":43,"coordinates":99},[86,87],{"lat":87,"lon":86},[102,103],{"name":91,"role":30,"phone":92,"phoneExt":32,"email":93},{"name":91,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":105,"status":37,"city":106,"state":32,"zip":107,"country":40,"countryCode":41,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Addenbrooke's Hospital","Cambridge","CB2 OQQ",{"type":43,"coordinates":109},[110,111],0.11667,52.2,{"lat":111,"lon":110},[114,118],{"name":115,"role":30,"phone":116,"phoneExt":32,"email":117},"Bristi Basu, Dr","01223 596105","bb313@medschl.cam.ac.uk",{"name":115,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":120,"status":37,"city":121,"state":32,"zip":122,"country":40,"countryCode":41,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Velindre Cancer Centre","Cardiff","CF14 2TL",{"type":43,"coordinates":124},[125,126],-3.18,51.48,{"lat":126,"lon":125},[129,134],{"name":130,"role":30,"phone":131,"phoneExt":132,"email":133},"Robert Jones, Dr","02920 615888","6327","Robert.Hugh.Jones@wales.nhs.uk",{"name":130,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":136,"status":70,"city":121,"state":32,"zip":137,"country":40,"countryCode":41,"cosmosGeoPoint":138,"geoPoint":140,"contacts":141},"Cardiff Children's Hospital","CF14 4XW",{"type":43,"coordinates":139},[125,126],{"lat":126,"lon":125},[142,146],{"name":143,"role":30,"phone":144,"phoneExt":32,"email":145},"Madeline Adams, Dr","02921842285","madeline.adams@wales.nhs.uk",{"name":143,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":148,"status":37,"city":149,"state":32,"zip":150,"country":40,"countryCode":41,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Western General Hospital","Edinburgh","EH4 2XU",{"type":43,"coordinates":152},[153,154],-3.19648,55.95206,{"lat":154,"lon":153},[157,159],{"name":158,"role":30,"phone":32,"phoneExt":32,"email":32},"Stefan Symeonides, Dr",{"name":158,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":161,"status":37,"city":162,"state":32,"zip":163,"country":40,"countryCode":41,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"The Beatson Hospital","Glasgow","G12 OYN",{"type":43,"coordinates":165},[166,167],-4.25763,55.86515,{"lat":167,"lon":166},[170,174],{"name":171,"role":30,"phone":172,"phoneExt":32,"email":173},"Patricia Roxburgh, Dr","0141 301 7118","Patricia.Roxburgh@glasgow.ac.uk",{"name":171,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":176,"status":37,"city":162,"state":32,"zip":177,"country":40,"countryCode":41,"cosmosGeoPoint":178,"geoPoint":180,"contacts":181},"Royal Hospital for Children Glasgow","G51 4TF",{"type":43,"coordinates":179},[166,167],{"lat":167,"lon":166},[182,186],{"name":183,"role":30,"phone":184,"phoneExt":32,"email":185},"Milind Ronghe, Dr","0141 452 6692","Milind.Ronghe@ggc.scot.nhs.uk",{"name":183,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":188,"status":37,"city":189,"state":32,"zip":190,"country":40,"countryCode":41,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Leicester Royal Infirmary","Leicester","LE1 5WW",{"type":43,"coordinates":192},[193,194],-1.13169,52.6386,{"lat":194,"lon":193},[197,201],{"name":198,"role":30,"phone":199,"phoneExt":32,"email":200},"Olubukola Ayodele, Dr","0116 2587601","olubukola.ayodele@uhl-tr.nhs.uk",{"name":198,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":203,"status":37,"city":204,"state":32,"zip":205,"country":40,"countryCode":41,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"Alder Hey Hospital","Liverpool","L14 5AB",{"type":43,"coordinates":207},[208,209],-2.97794,53.41058,{"lat":209,"lon":208},[212,216],{"name":213,"role":30,"phone":214,"phoneExt":32,"email":215},"Lisa Howell, Dr","0151 293 3679","Lisa.Howell@alderhey.nhs.uk",{"name":213,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":218,"status":37,"city":219,"state":32,"zip":220,"country":40,"countryCode":41,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"University College London Hospital","London","NW1 2BU",{"type":43,"coordinates":222},[223,224],-0.12574,51.50853,{"lat":224,"lon":223},[227,231],{"name":228,"role":30,"phone":229,"phoneExt":32,"email":230},"Martin Forster, Prof","020 3447 5085","M.Forster@ucl.ac.uk",{"name":228,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":233,"status":37,"city":219,"state":32,"zip":234,"country":40,"countryCode":41,"cosmosGeoPoint":235,"geoPoint":237,"contacts":238},"Guy's Hospital","SE1 9RT",{"type":43,"coordinates":236},[223,224],{"lat":224,"lon":223},[239,243],{"name":240,"role":30,"phone":241,"phoneExt":32,"email":242},"James Spicer, Dr","020 7188 4260","james.spicer@kcl.ac.uk",{"name":240,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":245,"status":37,"city":219,"state":32,"zip":246,"country":40,"countryCode":41,"cosmosGeoPoint":247,"geoPoint":249,"contacts":250},"Great Ormond Street Hospital","WC1N 3JH",{"type":43,"coordinates":248},[223,224],{"lat":224,"lon":223},[251,255],{"name":252,"role":30,"phone":253,"phoneExt":32,"email":254},"Darren Hargrave, Dr","0207 813 8525","Darren.hargrave@gosh.nhs.uk",{"name":252,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":257,"status":70,"city":258,"state":32,"zip":259,"country":40,"countryCode":41,"cosmosGeoPoint":260,"geoPoint":264,"contacts":265},"Royal Manchester Children's Hospital","Manchester","M13 9WL",{"type":43,"coordinates":261},[262,263],-2.23743,53.48095,{"lat":263,"lon":262},[266,270],{"name":267,"role":30,"phone":268,"phoneExt":32,"email":269},"Guy Makin, Dr","0161 701 8419","Guy.Makin@mft.nhs.uk",{"name":267,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":25,"status":37,"city":258,"state":32,"zip":272,"country":40,"countryCode":41,"cosmosGeoPoint":273,"geoPoint":275,"contacts":276},"M20 4BX",{"type":43,"coordinates":274},[262,263],{"lat":263,"lon":262},[277,280],{"name":24,"role":30,"phone":278,"phoneExt":32,"email":279},"01619187672","matthew.krebs@nhs.net",{"name":24,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":282,"status":37,"city":283,"state":32,"zip":284,"country":40,"countryCode":41,"cosmosGeoPoint":285,"geoPoint":289,"contacts":290},"Clatterbridge Cancer Centre","Metropolitan Borough of Wirral","CH63 4JY",{"type":43,"coordinates":286},[287,288],-3.10501,53.37616,{"lat":288,"lon":287},[291,295],{"name":292,"role":30,"phone":293,"phoneExt":32,"email":294},"Dan Palmer, Dr","0151 706 4172 \u002F 0151 706 4177","daniel.palmer@liverpool.ac.uk",{"name":292,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":297,"status":37,"city":298,"state":32,"zip":299,"country":40,"countryCode":41,"cosmosGeoPoint":300,"geoPoint":304,"contacts":305},"Great North Children's Hospital","Newcastle","NE1 4LP",{"type":43,"coordinates":301},[302,303],-5.88979,54.21804,{"lat":303,"lon":302},[306,310],{"name":307,"role":30,"phone":308,"phoneExt":32,"email":309},"Alastair Greystoke, Dr","0191 2138476","Alastair.Greystoke@newcastle.ac.uk",{"name":307,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":312,"status":37,"city":298,"state":32,"zip":313,"country":40,"countryCode":41,"cosmosGeoPoint":314,"geoPoint":316,"contacts":317},"Freeman Hospital","NE7 7DN",{"type":43,"coordinates":315},[302,303],{"lat":303,"lon":302},[318,320],{"name":307,"role":30,"phone":308,"phoneExt":32,"email":319},"Greystoke@newcastle.ac.uk",{"name":307,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":322,"status":37,"city":323,"state":32,"zip":324,"country":40,"countryCode":41,"cosmosGeoPoint":325,"geoPoint":329,"contacts":330},"Churchill Hospital","Oxford","OX3 7LE",{"type":43,"coordinates":326},[327,328],-1.25596,51.75222,{"lat":328,"lon":327},[331,335],{"name":332,"role":30,"phone":333,"phoneExt":32,"email":334},"Sarah Pratap, Dr","01865 235273","Sarah.Pratap@ouh.nhs.uk",{"name":332,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":337,"status":37,"city":323,"state":32,"zip":338,"country":40,"countryCode":41,"cosmosGeoPoint":339,"geoPoint":341,"contacts":342},"John Radcliffe Hospital","OX3 9DU",{"type":43,"coordinates":340},[327,328],{"lat":328,"lon":327},[343,344],{"name":332,"role":30,"phone":333,"phoneExt":32,"email":334},{"name":332,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":346,"status":37,"city":347,"state":32,"zip":348,"country":40,"countryCode":41,"cosmosGeoPoint":349,"geoPoint":353,"contacts":354},"Weston Park Hospital","Sheffield","S10 2SJ",{"type":43,"coordinates":350},[351,352],-1.4659,53.38297,{"lat":352,"lon":351},[355,359],{"name":356,"role":30,"phone":357,"phoneExt":32,"email":358},"Sarah Danson, Dr","0114 226 5068","s.danson@sheffield.ac.uk",{"name":356,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":361,"status":37,"city":347,"state":32,"zip":362,"country":40,"countryCode":41,"cosmosGeoPoint":363,"geoPoint":365,"contacts":366},"Sheffield's Children's Hospital","S10 2TH",{"type":43,"coordinates":364},[351,352],{"lat":352,"lon":351},[367,371],{"name":368,"role":30,"phone":369,"phoneExt":32,"email":370},"Daniel Yeomanson, Dr","01142717366","danyeomanson@nhs.net",{"name":368,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":373,"status":37,"city":374,"state":32,"zip":375,"country":40,"countryCode":41,"cosmosGeoPoint":376,"geoPoint":380,"contacts":381},"Southampton General Hospital","Southampton","SO16 6YD",{"type":43,"coordinates":377},[378,379],-1.40428,50.90395,{"lat":379,"lon":378},[382,386],{"name":383,"role":30,"phone":384,"phoneExt":32,"email":385},"Juliet Gray, Prof","0238 120 6639","Juliet.Gray@uhs.nhs.uk",{"name":383,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":388,"status":37,"city":389,"state":32,"zip":390,"country":40,"countryCode":41,"cosmosGeoPoint":391,"geoPoint":395,"contacts":396},"The Royal Marsden Hospital","Sutton","SM2 5PT",{"type":43,"coordinates":392},[393,394],-0.2,51.35,{"lat":394,"lon":393},[397,401],{"name":398,"role":30,"phone":399,"phoneExt":32,"email":400},"Lynley Marshall, Dr","0208 661 3678","LynleyVanessa.Marshall@icr.ac.uk",{"name":398,"role":26,"phone":32,"phoneExt":32,"email":32},{"type":403,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[405,407,409,411],{"name":406,"class":6},"University of Manchester",{"name":408,"class":6},"University of Birmingham",{"name":410,"class":6},"Royal Marsden NHS Foundation Trust",{"name":412,"class":413},"Hoffmann-La Roche","INDUSTRY","100498421",false,"NCT05770037","DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With ALK Positive Cancers","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With ALK Positive Cancers","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 01 (ALECTINIB) OUTLINED BELOW\\*\n\n\\*When alectinib-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the alectinib-specific criteria will take precedence.\n\nInclusion Criteria:\n\nA. Confirmed diagnosis of an ALK-positive malignancy using an analytically validated next-generation sequencing method.\n\nB. Women of childbearing potential are eligible, provided that they meet the following criteria:\n\n* Have a negative serum or urine pregnancy test before enrolment and;\n* Agree to use one form of highly effective birth control method such as:\n\nI. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal or transdermal\\]\n\nII. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable)\n\nIII. intrauterine device (IUD)\n\nIV. intrauterine hormone-releasing system (IUS)\n\nV. bilateral tubal occlusion\n\nVI. vasectomised partner\n\nVII. sexual abstinence\n\nEffective from the first administration of alectinib, throughout the trial and for three months after the last administration of alectinib.\n\nC. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from first administration of alectinib, throughout the trial and for three months after the last administration of alectinib:\n\n* Agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or sexual abstinence.\n* Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses a highly effective method of contraception, as in criterion B, above.\n* Male patients with pregnant or lactating partners must be advised to use barrier method contraception (e.g. condom) to prevent drug exposure of the foetus or neonate.\n\nAll male patients must refrain from donating sperm for the same period.\n\nD. Patients must be able and willing to undergo a fresh tissue biopsy. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nE. Paediatric patients (patients aged \\\u003C18 years) must have a body weight ≥40kg.\n\nF. ADULT PATIENTS (≥18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nG. PAEDIATRIC PATIENTS (\\\u003C18 years): Adequate organ function as per haematological and biochemical indices within the ranges shown below. These measurements should be performed to confirm the patient's eligibility.\n\nExclusion Criteria:\n\nA. Diagnosis of ALK-positive non-small cell lung cancer.\n\nB. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or for three months following their last dose of alectinib.\n\nC. Prior treatment with the same class of drug unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to alectinib. Patients who have previously received crizotinib (Xalkori\\^\\[®\\]) and did not respond, or who responded inadequately or responded adequately and subsequently progressed, are allowed into the trial.\n\nD. History of or radiological evidence of interstitial lung disease and\u002For pneumonitis. Prior localised radiotherapy related pneumonitis is permitted if resolved and off steroids and asymptomatic for \\>6 months.\n\nE. Patients at risk of gastrointestinal (GI) perforation e.g. history of diverticulitis, concomitant use of medicinal product with a recognized risk of GI perforation (unless patient has also been co-prescribed gastric protection).\n\n• Patients who present with a GI primary tumour or metastases to the GI tract may be considered.\n\nF. Patient unable to swallow or tolerate oral medication or any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or following major bowel resection. Paediatric patients will be excluded if they are unable to swallow the capsules, as per the dosing schedule (150 mg dose strength).\n\nG. Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias (within three months), or New York Heart Association (NYHA) class III or IV congestive heart failure.\n\nPatients with a cerebrovascular event (including stroke or transient ischaemic attack \\[TIA\\]), or cardiovascular event (including acute myocardial infarction \\[MI\\]), within three months before the first dose of alectinib.\n\n• Patients with primary CNS tumours may be considered unless intra-tumoural bleeding has occurred within 2 weeks of the first dose of alectinib, and patients with punctate CNS haemorrhages \\\u003C3 mm may be considered.\n\nH. History of organ transplantation.\n\nI. Symptomatic bradycardia for age.\n\nJ. Known hypersensitivity to alectinib or any of the excipients. See the current alectinib (Alecensa® 150 mg hard capsules) SmPC for the full list.\n\nK. Patients who were administered a live, attenuated vaccine within 28 days prior to enrolment, or anticipation of need for such a vaccine during alectinib treatment or within six months after the final dose of alectinib.\n\nL. Active hepatitis B or C virus or known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS) related illness. Patients with history of testing positive for HIV infection are eligible provided the each of the following conditions are met:\n\n* CD4 count ≥350\u002FμL;\n* undetectable viral load;\n* receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and\n* no HIV\u002FAIDS-associated opportunistic infection in the last 12 months.\n\nM. Familial or personal history of congenital bone disorders, bone metabolism alterations or known osteopenia in the patient.\n\nN. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial or absorption of oral medications or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.","ALL",{"count":423,"type":424},30,"ESTIMATED","INTERVENTIONAL",[427,428],"PHASE2","PHASE3","This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Alectinib works in lung cancer patients with a particular mutation in their cancer known as ALK.\n\nInvestigators now wish to find out if it will be useful in treating patients with other cancer types which have the same mutation. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[431,432,433,434,435,436,437,438,439,440,441],"Haematological Malignancy","Malignant Neoplasm","Lymphoproliferative Disorders","Neoplasms by Histologic Type","Neoplasms by Site","Cancer","Anaplastic Large Cell Lymphoma","Lymphoma","Renal Cell Carcinoma","Neuroblastoma","Solid Tumour",[443,17,444,445,436,446,447,448,449,450,451,435,452,453,454,455,456,457],"Adult","ALK Tyrosine Kinase Receptor","Antineoplastic Agents","Child","Malignancy","Malignant Neoplasms","Molecular Targeted Therapy","Mutation","Neoplasms by Histologic Site","Paediatric","Precision Medicine","Protein Kinase Inhibitors","Rare","Tumour-agnostic","Young adult","2025-11-19",{"date":460,"type":461},"2025-11-24","ACTUAL",{"date":463,"type":461},"2023-12-18",{"date":465,"type":424},"2029-10",{"name":5,"class":6},27]